Ovid Therapeutics (FRA:1OT) Short-Term Debt : €0.00 Mil (As of Mar. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Ovid Therapeutics Short-Term Debt?

Ovid Therapeutics's Short-Term Debt for the quarter that ended in Mar. 2024 was €0.00 Mil.

Ovid Therapeutics Short-Term Debt Historical Data

The historical data trend for Ovid Therapeutics's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ovid Therapeutics Short-Term Debt Chart

Ovid Therapeutics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Short-Term Debt

Get a 7-Day Free Trial

Ovid Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Short-Term Debt	Get a 7-Day Free Trial															-	-	-	-	-

Ovid Therapeutics Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Ovid Therapeutics Short-Term Debt Related Terms

Thank you for viewing the detailed overview of Ovid Therapeutics's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Ovid Therapeutics (FRA:1OT) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ovid Therapeutics Inc (FRA:1OT) » Definitions » Short-Term Debt

Comparable Companies

Traded in Other Exchanges

OVID:USA

Address

441 Ninth Avenue, 14th Floor, New York, NY, USA, 10001

Website

https://www.ovidrx.com

Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class or best-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.

Ovid Therapeutics (FRA:1OT) Headlines

No Headlines